TEVA EVP granted 33,424 restricted share units

TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026.

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.

The award vests in four equal installments of 8,356 units on March 4 of 2027, 2028, 2029, and 2030. The filing notes that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents one ordinary share.

Insider Trade Summary

Grant/Award: 33,424 shares

Grant/Award 1 txn

Insider Shields Matthew

Role EVP, Global Operations

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	33,424	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 33,424 contracts (Direct)

Footnotes (3)

1. F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2. F2. Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030.
3. F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA EVP Matthew Shields report on this Form 4?

Matthew Shields reported receiving a grant of 33,424 restricted share units. These units give him a contingent right to receive one ordinary share, or its cash value, for each unit upon settlement, subject to the vesting schedule.

How many restricted share units did Matthew Shields receive from TEVA?

He received 33,424 restricted share units. Each unit represents a contingent right to one ordinary share or its cash value, providing equity-based compensation that aligns his interests with shareholders as the units vest over time and potentially settle in shares or cash.

What is the vesting schedule for Matthew Shields’ TEVA restricted share units?

The 33,424 restricted share units vest in four equal installments of 8,356 units. Vesting occurs on March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, creating a multi-year retention and incentive structure for the executive.

What does each TEVA restricted share unit granted to Matthew Shields represent?

Each restricted share unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. Settlement will occur upon vesting, subject to the award’s terms and conditions.

How are TEVA ordinary shares related to American Depositary Shares mentioned in the filing?

The filing states that TEVA’s ordinary shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one ordinary share, linking the equity underlying the restricted share units to securities tradable in U.S. markets.

What role does Matthew Shields hold at TEVA in connection with this Form 4 grant?

Matthew Shields serves as Executive Vice President, Global Operations at TEVA. The reported transaction reflects an equity-based compensation grant of restricted share units tied to his executive position and subject to a four-year vesting schedule through 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shields Matthew

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Operations

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	03/04/2026		A		33,424		(2)	(2)	Ordinary Shares(3)	33,424	$0	33,424	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Matthew Shields	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.